IL6 and neoplasm: The carrier-free UA NPs exhibited the improved immunostimulatory activity of TNF-α, IL-6, and IFN-β in vitro and inhibited tumor growth with significant activation of CD4+ T cells in vivo, revealing their great potential for cancer immunotherapy.